These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 35583610)

  • 41. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma.
    Locke FL; Filosto S; Chou J; Vardhanabhuti S; Perbost R; Dreger P; Hill BT; Lee C; Zinzani PL; Kröger N; López-Guillermo A; Greinix H; Zhang W; Tiwari G; Budka J; Marincola FM; To C; Mattie M; Schupp M; Cheng P; Bot A; Shen R; Bedognetti D; Miao H; Galon J
    Nat Med; 2024 Feb; 30(2):507-518. PubMed ID: 38233586
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy.
    Badaracco J; Gitlin M; Keating SJ
    Transplant Cell Ther; 2023 Jan; 29(1):59.e1-59.e6. PubMed ID: 36272529
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma.
    Ghanem B
    Invest New Drugs; 2023 Oct; 41(5):710-718. PubMed ID: 37572232
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Next-Generation Chimeric Antigen Receptor T-cells.
    Yi D; Gergis M; Hsu J; Yang Y; Bi X; Aljurf M; Gergis U
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):117-121. PubMed ID: 36537905
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.
    Roddie C; Neill L; Osborne W; Iyengar S; Tholouli E; Irvine D; Chaganti S; Besley C; Bloor A; Jones C; Uttenthal B; Johnson R; Sanderson R; Cheok K; Marzolini M; Townsend W; O'Reilly M; Kirkwood AA; Kuhnl A
    Blood Adv; 2023 Jun; 7(12):2872-2883. PubMed ID: 36724512
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
    Abbasi A; Peeke S; Shah N; Mustafa J; Khatun F; Lombardo A; Abreu M; Elkind R; Fehn K; de Castro A; Wang Y; Derman O; Nelson R; Uehlinger J; Gritsman K; Sica RA; Kornblum N; Mantzaris I; Shastri A; Janakiram M; Goldfinger M; Verma A; Braunschweig I; Bachier-Rodriguez L
    J Hematol Oncol; 2020 Jan; 13(1):1. PubMed ID: 31900191
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
    Kato K; Fujii N; Makita S; Goto H; Kanda J; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Nakamura S; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
    Int J Hematol; 2023 Mar; 117(3):409-420. PubMed ID: 36399286
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
    Teoh J; Brown LF
    Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023.
    Ryan CE; Jacobson CA
    Semin Hematol; 2023 Nov; 60(5):322-328. PubMed ID: 38199906
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.
    Yamshon S; Gribbin C; Alhomoud M; Chokr N; Chen Z; Demetres M; Pasciolla M; Leonard J; Shore T; Martin P
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e235-e256.e2. PubMed ID: 38582666
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.
    Scholler N; Perbost R; Locke FL; Jain MD; Turcan S; Danan C; Chang EC; Neelapu SS; Miklos DB; Jacobson CA; Lekakis LJ; Lin Y; Ghobadi A; Kim JJ; Chou J; Plaks V; Wang Z; Xue A; Mattie M; Rossi JM; Bot A; Galon J
    Nat Med; 2022 Sep; 28(9):1872-1882. PubMed ID: 36038629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel.
    Fried S; Shouval R; Varda-Bloom N; Besser MJ; Yerushalmi R; Shem-Tov N; Danylesko I; Jacoby E; Teihman S; Itzhaki O; Fein JA; Kedmi M; Shimoni A; Nagler A; Avigdor A
    Leuk Lymphoma; 2022 Dec; 63(14):3385-3393. PubMed ID: 36111694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma.
    Steiner RE; Banchs J; Koutroumpakis E; Becnel M; Gutierrez C; Strati P; Pinnix CC; Feng L; Rondon G; Claussen C; Palaskas N; Karimzad K; Ahmed S; Neelapu SS; Shpall E; Wang M; Vega F; Westin J; Nastoupil LJ; Deswal A
    Haematologica; 2022 Jul; 107(7):1555-1566. PubMed ID: 34758610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis.
    Mian A; Wei W; Winter AM; Khouri J; Jagadeesh D; Anwer F; Gerds AT; Dean RM; Sobecks R; Pohlman B; Hamilton BK; Majhail NS; Hill BT
    Leuk Lymphoma; 2021 Jun; 62(6):1344-1352. PubMed ID: 33375873
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.
    Wright CM; LaRiviere MJ; Baron JA; Uche C; Xiao Y; Arscott WT; Anstadt EJ; Barsky AR; Miller D; LaRose MI; Landsburg DJ; Svoboda J; Nasta SD; Gerson JN; Barta SK; Chong EA; Schuster SJ; Paydar I; Maity A; Plastaras JP
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):178-188. PubMed ID: 32446950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.
    Jacobs MT; Jain MD; Gao F; Nastoupil LJ; Spiegel JY; Lin Y; Dahiya S; Lunning M; Lekakis L; Reagan PM; Oluwole OO; McGuirk J; Deol A; Sehgal A; Goy A; Hill BT; Andreadis C; Munoz J; Chavez JC; Bennani NN; Rapoport AP; Vose JM; Miklos DB; Neelapu SS; Ghobadi A; Locke FL
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):753-759. PubMed ID: 35780055
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.
    Iovino L; Wu QV; Voutsinas J; Panaite L; Mullane E; Lynch RC; Ujjani C; Smith SD; Gopal AK; Till BG; Milano F; Chow V; Gauthier J; Turtle CJ; Maloney DG; Shadman M
    J Cell Mol Med; 2022 Dec; 26(24):5976-5983. PubMed ID: 36453136
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
    Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
    J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.